# Isomorphic Labs

Source: https://onco.cc/companies/isomorphic-labs/  
OnCo record `isomorphic-labs` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Alphabet's AlphaFold-derived drug design company; its first AI-designed oncology candidate was cleared for human trials in January 2026 after a $2.1B raise.

## Summary

Isomorphic Labs, based in London, is Alphabet's AlphaFold-derived drug design company, whose first AI-designed oncology candidate was cleared for human trials in January 2026 after a raise of about 2.1 billion dollars. It co-developed AlphaFold 3 with Google DeepMind, built the IsoDDE design engine, and had ISM8969 cleared by the FDA for a first-in-human study on 28 January 2026, with an initial pipeline in oncology and immunology and partnerships with Eli Lilly and Novartis. OnCo links it to AI-driven drug and target discovery, AlphaFold 3 and de novo designed protein binders, and to the idea of AI-designed proteins that grip the floppy parts of cancer drivers. The valley of death between lab and product is the bottleneck its first trial now enters. Whether structure prediction shortens development or only the discovery step is the open question.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- Tags: frontier
- HQ: London
- Type: ai-software
- Website: https://www.isomorphiclabs.com

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Isomorphic_Labs
- Trials of AI-designed drugs: https://www.clinicaltrialsarena.com/news/isomorphic-labs-prepares-trials-ai-designed-drugs/

## Connected records

- fronts: [AI & Computation](https://onco.cc/fronts/ai-computation/), [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/)
- technologies: [AI-driven drug & target discovery](https://onco.cc/technologies/ai-drug-design/), [AlphaFold 3](https://onco.cc/technologies/alphafold3/), [De novo designed protein binders](https://onco.cc/technologies/de-novo-protein-design/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/), [Google DeepMind (and Google Research)](https://onco.cc/companies/google-deepmind/), [GV (Google Ventures)](https://onco.cc/companies/gv/), [Novartis](https://onco.cc/companies/novartis/)
- bottlenecks: [The valley of death between lab and product](https://onco.cc/bottlenecks/b-translational-valley/)
- ideas: [AI-designed proteins that grip the floppy parts of cancer drivers](https://onco.cc/ideas/idea-bio1-ai-binders-disordered-regions/)
- institutions: [EMBL's European Bioinformatics Institute](https://onco.cc/institutions/embl-ebi/)
- roadmaps: [AI in oncology roadmap: pattern readers → foundation models → agents in the workflow](https://onco.cc/roadmaps/ai-oncology-roadmap/), [Drug discovery roadmap: screening in mice → maps of dependency → designing in silico](https://onco.cc/roadmaps/drug-discovery-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/isomorphic-labs.json